Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13516MR)

This product GTTS-WQ13516MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13516MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12697MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ114MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ7957MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ15084MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ2899MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ2869MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ694MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ10812MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M7824
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW